Skip Nav Destination
Issues
1 September 2021
-
Cover Image
Cover Image
Antigen-presenting cells expressing MHC II (green) form niches together with exhausted progenitor T cells expressing CD8 (red, membranous) and TCF1 (light blue, nuclear). Although prostate cancer is classically nonimmunogenic, these tumor-infiltrating immune populations are seen in a uniquely immunogenic subset of localized prostate cancer and are consistent with an antitumor immune response, which may be further expanded by immune checkpoint blockade. For details, see the article by Calagua and colleagues on page 4836 of this issue. (Image created by C.S. Jansen, co-author.) - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Review
CCR Drug Updates
FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma
Sandra J. Casak; Leigh Marcus; Lola Fashoyin-Aje; Sirisha L. Mushti; Joyce Cheng; Yuan-Li Shen; William F. Pierce; Leah Her; Kirsten B. Goldberg; Marc R. Theoret; Paul G. Kluetz; Richard Pazdur; Steven J. Lemery
Research Briefs: Clinical Trial Brief Reports
Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
Matthew S. Davids; Andrew W. Roberts; Vaishalee P. Kenkre; William G. Wierda; Abhijeet Kumar; Thomas J. Kipps; Michelle Boyer; Ahmed Hamed Salem; John C. Pesko; Jennifer A. Arzt; Margaret Mantas; Su Y. Kim; John F. Seymour
Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY)
Judy C. Boughey; Vera J. Suman; Jia Yu; Katelyn Santo; Jason P. Sinnwell; Jodi M. Carter; Krishna R. Kalari; Xiaojia Tang; Sarah A. McLaughlin; Alvaro Moreno-Aspitia; Donald W. Northfelt; Richard J. Gray; Katie N. Hunt; Amy Lynn Conners; James N. Ingle; Ann Moyer; Richard Weinshilboum; John A. Copland, III; Liewei Wang; Matthew P. Goetz
Clinical Trials: Targeted Therapy
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
Seung Tae Kim; Simon A. Smith; Peter Mortimer; Arsene-Bienvenu Loembé; Heejin Cho; Kyoung-Mee Kim; Claire Smith; Sophie Willis; Itziar Irurzun-Arana; Alienor Berges; Jung Yong Hong; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Iwanka Kozarewa; Andrew J. Pierce; Emma Dean; Jeeyun Lee
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors
Khanh T. Do; Bose Kochupurakkal; Sarah Kelland; Adrienne de Jonge; Jennifer Hedglin; Allison Powers; Nicholas Quinn; Courtney Gannon; Loan Vuong; Kalindi Parmar; Jean-Bernard Lazaro; Alan D. D'Andrea; Geoffrey I. Shapiro
Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma
James M. Kilgour; Aatman Shah; Nicole M. Urman; Shaundra Eichstadt; Hanh N. Do; Irene Bailey; Amar Mirza; Shufeng Li; Anthony E. Oro; Sumaira Z. Aasi; Kavita Y. Sarin
Clinical Trials: Immunotherapy
Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma
Joseph M. Tuscano; Christina Poh; Paul Kaesberg; Guilluame Luxardi; Alexander Merleev; Alina Marusina; Ann Brunson; Aaron Rosenberg; Brian Jonas; Emanual Maverakis
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases
Anna Maria Di Giacomo; Vanna Chiarion-Sileni; Michele Del Vecchio; Pier Francesco Ferrucci; Michele Guida; Pietro Quaglino; Massimo Guidoboni; Paolo Marchetti; Ornella Cutaia; Giovanni Amato; Alessia Covre; Roberto Camerini; Luana Calabrò; Monica Valente; Diana Giannarelli; Mario Mandalà; Michele Maio
A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
Lawrence Fong; Michael J. Morris; Oliver Sartor; Celestia S. Higano; Lance Pagliaro; Ajjai Alva; Leonard J. Appleman; Winston Tan; Ulka Vaishampayan; Raphaelle Porcu; Darren Tayama; Edward E. Kadel, III; Kobe C. Yuen; Asim Datye; Andrew J. Armstrong; Daniel P. Petrylak
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Sarah A. Weiss; Dijana Djureinovic; Shlomit Jessel; Irina Krykbaeva; Lin Zhang; Lucia Jilaveanu; Amanda Ralabate; Barbara Johnson; Neta Shanwetter Levit; Gail Anderson; Daniel Zelterman; Wei Wei; Amit Mahajan; Ovid Trifan; Marcus Bosenberg; Susan M. Kaech; Curtis J. Perry; William Damsky; Scott Gettinger; Mario Sznol; Michael Hurwitz; Harriet M. Kluger
Precision Medicine and Imaging
Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
Laetitia Marisa; Yuna Blum; Julien Taieb; Mira Ayadi; Camilla Pilati; Karine Le Malicot; Côme Lepage; Ramon Salazar; Daniela Aust; Alex Duval; Hélène Blons; Valérie Taly; David Gentien; Audrey Rapinat; Janick Selves; Sophie Mouillet-Richard; Valérie Boige; Jean-François Emile; Aurélien de Reyniès; Pierre Laurent-Puig
Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform
Durga Udayakumar; Ze Zhang; Yin Xi; Durgesh K. Dwivedi; Michael Fulkerson; Sydney Haldeman; Tiffani McKenzie; Qurratulain Yousuf; Allison Joyce; Asghar Hajibeigi; Hollis Notgrass; Alberto Diaz de Leon; Qing Yuan; Matthew A. Lewis; Ananth J. Madhuranthakam; Robert C. Sibley; Roy Elias; Junyu Guo; Alana Christie; Renée M. McKay; Jeffrey A. Cadeddu; Aditya Bagrodia; Vitaly Margulis; James Brugarolas; Tao Wang; Payal Kapur; Ivan Pedrosa
Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma
Zeynep B. Zengin; Caroline Weipert; Nicholas J. Salgia; Nazli Dizman; Joann Hsu; Luis Meza; Alexander Chehrazi-Raffle; Ramya Muddasani; Sabrina Salgia; Jasnoor Malhotra; Neal Chawla; Errol J. Philip; Lesli Kiedrowski; Benjamin L. Maughan; Nityam Rathi; Divyam Goel; Toni K. Choueiri; Neeraj Agarwal; Sumanta K. Pal
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model
Max J. Gordon; Andy Kaempf; Andrea Sitlinger; Geoffrey Shouse; Matthew Mei; Danielle M. Brander; Tareq Salous; Brian T. Hill; Hamood Alqahtani; Michael Choi; Michael C. Churnetski; Jonathon B. Cohen; Deborah M. Stephens; Tanya Siddiqi; Xavier Rivera; Daniel Persky; Paul Wisniewski; Krish Patel; Mazyar Shadman; Byung Park; Alexey V. Danilov
Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type
Takaaki Konuma; Junya Kanda; Yachiyo Kuwatsuka; Masamitsu Yanada; Tadakazu Kondo; Shigeki Hirabayashi; Shinichi Kako; Yu Akahoshi; Naoyuki Uchida; Noriko Doki; Yukiyasu Ozawa; Masatsugu Tanaka; Tetsuya Eto; Masashi Sawa; Satoshi Yoshioka; Takafumi Kimura; Yoshinobu Kanda; Takahiro Fukuda; Yoshiko Atsuta; Fumihiko Kimura
Translational Cancer Mechanisms and Therapy
A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes
Carla Calagua; Miriam Ficial; Caroline S. Jansen; Taghreed Hirz; Luke del Balzo; Scott Wilkinson; Ross Lake; Anson T. Ku; Olga Voznesensky; David B. Sykes; Philip J. Saylor; Huihui Ye; Sabina Signoretti; Haydn Kissick; Adam G. Sowalsky; Steven P. Balk; David J. Einstein
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
Richard S. Finn; Masatoshi Kudo; Ann-Lii Cheng; Lucjan Wyrwicz; Roger K.C. Ngan; Jean-Frederic Blanc; Ari D. Baron; Arndt Vogel; Masafumi Ikeda; Fabio Piscaglia; Kwang-Hyub Han; Shukui Qin; Yukinori Minoshima; Michio Kanekiyo; Min Ren; Ryo Dairiki; Toshiyuki Tamai; Corina E. Dutcus; Hiroki Ikezawa; Yasuhiro Funahashi; Thomas R. Jeffry Evans
Memory-like Differentiation Enhances NK Cell Responses to Melanoma
Nancy D. Marin; Bradley A. Krasnick; Michelle Becker-Hapak; Leah Conant; Simon P. Goedegebuure; Melissa M. Berrien-Elliott; Keenan J. Robbins; Jennifer A. Foltz; Mark Foster; Pamela Wong; Celia C. Cubitt; Jennifer Tran; Christopher B. Wetzel; Miriam Jacobs; Alice Y. Zhou; David Russler-Germain; Lynne Marsala; Timothy Schappe; Ryan C. Fields; Todd A. Fehniger
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Carmine De Angelis; Xiaoyong Fu; Maria Letizia Cataldo; Agostina Nardone; Resel Pereira; Jamunarani Veeraraghavan; Sarmistha Nanda; Lanfang Qin; Vidyalakshmi Sethunath; Tao Wang; Susan G. Hilsenbeck; Matteo Benelli; Ilenia Migliaccio; Cristina Guarducci; Luca Malorni; Lacey M. Litchfield; Jiangang Liu; Joshua Donaldson; Pier Selenica; David N. Brown; Britta Weigelt; Jorge S. Reis-Filho; Ben H. Park; Sara A. Hurvitz; Dennis J. Slamon; Mothaffar F. Rimawi; Valerie M. Jansen; Rinath Jeselsohn; C. Kent Osborne; Rachel Schiff
RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
Siang-Boon Koh; Kenneth Ross; Steven J. Isakoff; Nsan Melkonjan; Lei He; Karina J. Matissek; Andrew Schultz; Erica L. Mayer; Tiffany A. Traina; Lisa A. Carey; Hope S. Rugo; Minetta C. Liu; Vered Stearns; Adam Langenbucher; Srinivas Vinod Saladi; Sridhar Ramaswamy; Michael S. Lawrence; Leif W. Ellisen
ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer
Zhe Tang; Patrick G. Pilié; Chuandong Geng; Ganiraju C. Manyam; Guang Yang; Sanghee Park; Daoqi Wang; Shan Peng; Cheng Wu; Guang Peng; Timothy A. Yap; Paul G. Corn; Bradley M. Broom; Timothy C. Thompson
Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner
Tingting Liu; Vi Lam; Elana Thieme; Duanchen Sun; Xiaoguang Wang; Fei Xu; Lili Wang; Olga V. Danilova; Zheng Xia; Jeffrey W. Tyner; Stephen E. Kurtz; Alexey V. Danilov
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Dae-Hwan Kim; Duanchen Sun; William K. Storck; Katherine Welker Leng; Chelsea Jenkins; Daniel J. Coleman; David Sampson; Xiangnan Guan; Anbarasu Kumaraswamy; Eva S. Rodansky; Joshua A. Urrutia; Jacob A. Schwartzman; Chao Zhang; Himisha Beltran; Mark P. Labrecque; Colm Morrissey; Jared M. Lucas; Ilsa M. Coleman; Peter S. Nelson; Eva Corey; Samuel K. Handelman; Jonathan Z. Sexton; Rahul Aggarwal; Wassim Abida; Felix Y. Feng; Eric J. Small; Daniel E. Spratt; Armand Bankhead, III; Arvind Rao; Emily M. Gesner; Sarah Attwell; Sanjay Lakhotia; Eric Campeau; Joel A. Yates; Zheng Xia; Joshi J. Alumkal
Letter to the Editor
Corrections
Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Carmine De Angelis; Xiaoyong Fu; Maria Letizia Cataldo; Agostina Nardone; Resel Pereira; Jamunarani Veeraraghavan; Sarmistha Nanda; Lanfang Qin; Vidyalakshmi Sethunath; Tao Wang; Susan G. Hilsenbeck; Matteo Benelli; Ilenia Migliaccio; Cristina Guarducci; Luca Malorni; Lacey M. Litchfield; Jiangang Liu; Joshua Donaldson; Pier Selenica; David N. Brown; Britta Weigelt; Jorge S. Reis-Filho; Ben H. Park; Sara A. Hurvitz; Dennis J. Slamon; Mothaffar F. Rimawi; Valerie M. Jansen; Rinath Jeselsohn; C. Kent Osborne; Rachel Schiff
Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer
Arta M. Monjazeb; Anita Giobbie-Hurder; Ana Lako; Emily M. Thrash; Ryan C. Brennick; Katrina Z. Kao; Claire Manuszak; Ryan D. Gentzler; Anteneh Tesfaye; Salma K. Jabbour; Olatunji B. Alese; Osama E. Rahma; James M. Cleary; Elad Sharon; Harvey J. Mamon; May Cho; Howard Streicher; Helen X. Chen; Mansoor M. Ahmed; Adrian Mariño-Enríquez; Seunghee Kim-Schulze; Sacha Gnjatic; Emanual Maverakis; Alina I. Marusina; Alexander A. Merleev; Mariano Severgnini; Kathleen L. Pfaff; James Lindsay; Jason L. Weirather; Srinika Ranasinghe; Alexander Spektor; Scott J. Rodig; F. Stephen Hodi; Jonathan D. Schoenfeld
Correction: Effects of Tobacco Smoking On the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma
Janis V. de la Iglesia; Robbert J.C. Slebos; Laura Martin-Gomez; Xuefeng Wang; Jamie K. Teer; Aik Choon Tan; Travis A. Gerke; Garrick Aden-Buie; Tessa van Veen; Jude Masannat; Ritu Chaudhary; Feifei Song; Michelle Fournier; Erin M. Siegel; Matthew B. Schabath; J. Trad Wadsworth; Jimmy Caudell; Louis Harrison; Bruce M. Wenig; Jose Conejo-Garcia; Juan C. Hernandez-Prera; Christine H. Chung
Correction: Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell–like Phenotype via Dysregulation of PITX2
Jia-Xing Zhang; Zhen-Hua Chen; Yi Xu; Jie-Wei Chen; Hui-Wen Weng; Miao Yun; Zou-San Zheng; Cui Chen; Bing-Li Wu; En-Min Li; Jian-Hua Fu; Sheng Ye; Dan Xie
Editor’s Note
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.